These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5418502)

  • 1. Irreversible enzyme inhibitors. 168. Irreversible inhibition of dihydrofolate reductase and cell wall transport by pyrimidines and dihydro-s-triazines with pyridinium side chains.
    Baker BR; Vermeulen NM; Ryan AJ
    J Med Chem; 1970 Mar; 13(2):280-4. PubMed ID: 5418502
    [No Abstract]   [Full Text] [Related]  

  • 2. Irreversible enzyme inhibitors. CLX. Some factors in cell wall transport of active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines.
    Baker BR; Janson EE; Vermeulen NM
    J Med Chem; 1969 Sep; 12(5):898-902. PubMed ID: 5812208
    [No Abstract]   [Full Text] [Related]  

  • 3. Irreversible enzyme inhibitors. CLXXVII. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines. II.
    Baker BR; Vermeulen NM
    J Med Chem; 1970 Nov; 13(6):1154-60. PubMed ID: 5479856
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible enzyme inhibitors. 198. Diaminodihydro-S-triazines and diaminopyrimidines bearing substituted (ureidomethyl)phenyl substituents as reversible inhibitors of dihydrofolate reductase.
    Ashton WT; Kirk LL; Baker BR
    J Med Chem; 1973 May; 16(5):453-6. PubMed ID: 4736964
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5793161
    [No Abstract]   [Full Text] [Related]  

  • 6. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5822623
    [No Abstract]   [Full Text] [Related]  

  • 7. Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. II.
    Baker BR; Vermuelen NM
    J Med Chem; 1969 Jul; 12(4):684-8. PubMed ID: 5793162
    [No Abstract]   [Full Text] [Related]  

  • 8. Irreversible enzyme inhibitors. CLIV. Some factors in cell wall transport of active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-substituted 2,4-diaminopyrimidines.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jul; 12(4):668-71. PubMed ID: 5793159
    [No Abstract]   [Full Text] [Related]  

  • 9. Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1165-70. PubMed ID: 5479858
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreversible enzyme inhibitors. CLIX. Effect of substitution on transport and isozyme specificity of p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)-o-chlorophenoxyacetamido-benzenesulfonyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Baker BR; Ashton WT
    J Med Chem; 1969 Sep; 12(5):894-7. PubMed ID: 5812207
    [No Abstract]   [Full Text] [Related]  

  • 11. Irreversible enzyme inhibitors. 196. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine and bearing a terminal phenyl sulfonate group.
    Baker BR; Ashton WT
    J Med Chem; 1972 Sep; 15(9):945-7. PubMed ID: 5051014
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible enzyme inhibitors. 178. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1161-5. PubMed ID: 5479857
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
    Selassie CD; Strong CD; Hansch C; Delcamp TJ; Freisheim JH; Khwaja TA
    Cancer Res; 1986 Feb; 46(2):744-56. PubMed ID: 3940640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
    Baker BR; Lourens GJ; Meyer RB; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):67-73. PubMed ID: 5763043
    [No Abstract]   [Full Text] [Related]  

  • 15. Irreversible enzyme inhibitors. CLXXVI. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine by ether bridging to a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1149-54. PubMed ID: 5479855
    [No Abstract]   [Full Text] [Related]  

  • 16. Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
    Baker BR
    J Med Chem; 1968 May; 11(3):483-6. PubMed ID: 5241406
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible enzyme inhibitors. CXLI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[p-(p-fluorosulfonylphenylureidomethyl)phenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):101-4. PubMed ID: 5763002
    [No Abstract]   [Full Text] [Related]  

  • 18. Irreversible enzyme inhibitors. CV. Differential irreversible inhibition of vertebrate dihydrofolic reductases by derivatives of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazines substituted with a terminal sulfonyl fluoride.
    Baker BR; Lourens GJ
    J Med Chem; 1967 Nov; 10(6):1113-22. PubMed ID: 6056040
    [No Abstract]   [Full Text] [Related]  

  • 19. Irreversible enzyme inhibitors. CLV. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[4-(omega-aminoalkoxy)-3-chlorophenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazines bearing a terminal sulfonyl fluoride.
    Baker BR; Janson EE
    J Med Chem; 1969 Jul; 12(4):672-6. PubMed ID: 5793160
    [No Abstract]   [Full Text] [Related]  

  • 20. Irreversible enzyme inhibitors. CXL. Active-site-directed irreversible inhibitors derived from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):95-101. PubMed ID: 5763050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.